Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with Bacillus Calmette-Guérin (BCG)

European Urology

Volumn 45, Issue 4, 2004, Pages 475-482

  Saint, Fabien ^a,b   Le Frere Belda, Marie Aude ^a   Quintela, Rodrigo ^a   Hoznek, Andras ^a   Patard, Jean Jacques ^a   Bellot, Jacqueline ^a   Popov, Zivko ^a   Zafrani, Elie S ^a   Abbou, Claude C ^a   Chopin, Dominique K ^a   De Medina, Sixtina Gil Diez ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

Author keywords

BCG therapy; Bladder cancer; p53; Tumor suppressor gene

Indexed keywords

BCG CONNAUGHT IMMUCYST; BCG IMMUN F; BCG VACCINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DO7; PARAFFIN; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ANAMNESIS; ARTICLE; BLADDER CANCER; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFECT; FEMALE; GENE OVEREXPRESSION; HIGH RISK POPULATION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENT DISEASE; RISK ASSESSMENT; TRANSITIONAL CELL CARCINOMA;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; CARCINOMA, TRANSITIONAL CELL; CELL NUCLEUS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 12144288735     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2003.11.018     Document Type: Article

References (37)

1. Morales A., Eidinger D., Bruce A.W. Intracavity Bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J. Urol. 116:1976;180-183.
2. Herr H.W., Laudone V.P., Badalament R.A., Oettgen H.F., Pramod C.S., Freedman B.D.et al. Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer. J. Clin. Oncol. 6:1988;1450-1455.
3. Merz V.W., Marth D., Kraft D., Ackermann D.K., Zingg E.J., Studer U.E. Analysis of early failures after intravesical instillation therapy with Bacillus Calmette-Guérin for carcinoma in situ of the bladder. Br. J. Urol. 75:1995;180-184.
4. Herr H.W., Sogani P.C. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors? J. Urol. 166:2001;1296-1299.
5. Yiou R., Patard J.J., Benhard C.C., Abbou C.C., Chopin D.K. Outcome of radical cystectomy for bladder cancer according to the disease type at presentation. BJU Int. 89:2002;374-378.
6. Nakopoulou L., Vourlakou C., Zervas A., Tzonou A., Gakiopoulou H., Dimopoulos M.A. The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinoma and their clinicopathologic correlates. Hum. Pathol. 29:1998;146-154.
7. Popov Z., Hoznek A., Colombel M., Bastuji-Garin S., Lefrere-Belda M.A., Bellot J.et al. The prognostic value of p53 nuclear overexpression and MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder. Cancer. 80:1997;1472-1481.
8. Ovesen H., Horn T., Steven K. Long-term efficacy of intravesical Bacillus Calmette-Guérin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation. J. Urol. 157:1997;1655-1659.
9. Lebret T., Becette V., Barbagelatta M., Herve J.M., Gaudez F., Barre P. et al. Correlation between p53 over expression and response to Bacillus Calmette-Guérin therapy in a high risk select population of patients with T1G3 bladder cancer. J. Urol. 159:1998;788-791.
10. WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with Bacillus Calmette-Guérin intravesical therapy. J. Urol. 161:1999;792-798.
11. Peyromaure M., Weibing S., Sebe P., Verpillat P., Toublanc M., Dauge M.C.et al. Prognostic value of p53 overexpression in T1G3 bladder tumors treated with Bacilus Calmette-Guérin therapy. Urology. 59:2002;409-413.
12. Pages F., Flam T.A., Vieillefond A., Molinie V., Abeille X., Lazar V.et al. p53 status does not predict initial clinical response to Bacillus Calmette-Guérin intravesical therapy in T1 bladder tumors. J. Urol. 159:1998;1079-1084.
13. Jacobs T.W., Prioleau J.E., Stillman I.E., Schnitt S.J. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J. Natl. Cancer. Inst. 88:1996;1054-1059.
14. Sobin LH, Wittekind Ch, editors. UICC/TNM Classification of malignant tumours. 5th ed. New York: John Wiley; 1997.
15. Mostofi FK, Sobin LH, Torloni H. Histological typing of urinary bladder tumours. International histological classification of tumours, N°10. Geneva: World Health Organization; 1973.
16. Lacombe L., Dalbagni G., Zhang Z.F., Cordon-Cardo C., Fair W.R., Herr H.W.et al. Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after Bacillus Calmette- Guérin therapy: correlation to clinical outcome. J. Clin. Oncol. 14:1996;2646-2652.
17. Cox D.R. Partial likelihood. Biometrika. 62:1975;269-279.
18. Levine A.J., Momand J., Finlay C.A. The p53 tumour suppressor gene. Nature. 351:1991;453-456.
19. Slaton J.W., Benedict W.F., Dinney C.P.N. p53 in bladder cancer: mechanism of action, prognostic value, and target for therapy. Urology. 57:2001;852-859.
20. Hall P.A., Meek D., Lane D.P. p53 integrating the complexity. J. Pathol. 180:1996;1-5.
21. Nishizaki M., Fujiwara T., Tanida T., Hizuta A., Nishimori H., Tokino T.et al. Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanisms for bystander effect. Clin. Cancer. Res. 5:1999;1015-1023.
22. Vollmer R.T., Humphrey P.A., Swanson P.E., Wick M.R., Hudson M.A. Invasion of the bladder by transitional cell carcinoma: its relation to histologic grade and expression of p53, MIB-1, c-erb B-2, Epidermal Growth Factor Receptor, and bcl-2. Cancer. 82:1998;715-723.
23. Bernardini S., Adessi G.L., Billerey C., Chezy E., Carbillet J.P., Bittard H. Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinoma. J. Urol. 162:1999;1496-1501.
24. Serth J., Kuczyk M.A., Bokemeyer C., Hervatin C., Nafe R., Tan H.K.et al. p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br. J. Cancer. 71:1995;201-205.
25. Llopis J., Alcaraz A., Ribal M.J., Sole M., Ventura P.J., Barranco M.A. et al. p53 expression predicts progression and poor survival in T1 bladder tumours. Eur. Urol. 37:2000;644-653.
26. Steiner G., Bierhoff E., Schmidt D., Leisner J., Wolf H.K., Albers P. p53 immunoreactivity in biopsy specimens of T1G3 transitional cell carcinoma of the bladder: a helpful parameter in guiding the decision for or against cystectomy? Eur. J. Cancer. 36:2000;610-614.
27. Wolf H.K., Stober C., Hohenfellner R., Leissner J. Prognostic value of p53, p21/WAF1, Bcl-2, Bax, Bak, and Ki-67 immunoreactivity in pT1G3 urothelial bladder carcinomas. Tumor. Biol. 22:2001;328-336.
28. Liukkonen T., Rajala P., Raitanen M., Rintala E., Kaasinen E., Lipponen P. Prognostic value of MIB-1 score p53, EGFr, mitotic index and papillary status in primary superficial (stage pTa/T1) bladder cancer: a prospective comparative study. The finnbladder group. Eur. Urol. 36:1999;393-400.
29. Wu T.T., Chen J.H., Lee Y.H., Huang J.K. The role of BCL-2, p53, and KI-67 index in predicting tumor recurrence for low grade superficial transitional cell bladder carcinoma. J. Urol. 163:2000;758-760.
30. Bernardini S., Billerey C., Martin M., Adessi G.L., Wallerand H., Bittard H. The predictive value of muscularis mucosae invasion and p53 over expression on progression of stage T1 bladder carcinoma. J. Urol. 165:2001;42-46.
31. Pfister C., Flaman J.M., Dunet F., Grise P., Frebourg T. P53 mutations in bladder tumors inactivate the transactivation of the P21 and BAX genes, and have a predictive value for the clinical outcome after Bacillus Calmette-Guérin. J. Urol. 162:1999;69-73.
32. Ick K., Schultz M., Stout P., Fan K. Significance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after Bacillus Calmette-Guérin treatment. Urology. 49:1997;541-547.
33. Beckstead J.H. Improved antigen retrieval in formalin-fixed, paraffin-embedded tissues. Appl. Immunohistochem. 2:1994;274-281.
34. Henson D.E. Loss of p53-immunostaining intensity in breast cancer [Editorial]. J. Natl. Cancer. Inst. 88:1996;1015-1016.
35. McShane L.M., Aamodt R., Cordon-Cardo C., Cote R., Faraggi D., Fradet Y.et al. Reproducibility of p53 immunohistochemistry in bladder tumors. Clin. Cancer. Res. 6:2000;1854-1864.
36. Sjogren S., Inganas M., Norberg T., Lindgren A., Nordgren H., Holmberg L.et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J. Natl. Cancer. Inst. 88:1996;173-182.
37. Casagrande J.T., Pike M.C., Smith P.G. An improved approximate formula for calculating sample sizes for comparing two binomial distributions. Biometrics. 34:1978;483-486.